Inclusion Criteria:

          1. Histologically or cytologically confirmed recurrent or advanced solid cancers with
             PI3K/ATK aberration

          2. Progressive disease who failed to previous standard treatment.

          3. At least one measurable lesion according to Response Evaluation Criteria in Solid
             Tumors version 1.1 criteria

          4. Eastern Cooperative Oncology Group performance status 0 or 1

          5. Able to take medications orally

          6. Adequate organ function

          7. A life expectancy of at least 60 days

        Exclusion Criteria:

          1. Previous treatment with anti-PI3K or AKT directed therapies

          2. Known hypersensitivity to any drugs similar to TAS-117 in structure or class.

          3. History or current evidence of type 1 or type 2 diabetes mellitus that requires
             insulin and/or oral antidiabetic therapy.

          4. Current evidence of retinopathy that requires ophthalmological therapy.

          5. History or current evidence of cardiac arrhythmia and/or conduction abnormality.

          6. Treatment with any of the following within the specified time frame prior to study
             drug administration:

               -  Major surgery within prior 4 weeks

               -  Radiation therapy for extended field within 4 weeks prior to study drug
                  administration or limited field radiation therapy within 2 weeks prior to study
                  drug administration.

               -  Any anticancer treatment within 3 weeks prior to study drug administration
                  (mitomycin within prior 5 weeks).

          7. A serious illness or medical condition(s)

          8. Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding alopecia,
             skin pigmentation and anemia).

          9. Patients with the risk of hypokalemia

         10. Receiving oral steroid medication.

         11. Pregnant or lactating female